2 hours ago 1

Metsera, Inc. (MTSR)’s MET-233i Shows 8% Weight Loss in Phase 1

Thu, Sep 11, 2025, 10:14 AM 1 min read

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Metsera, Inc. is one of them.

Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biotech based in New York, is emerging as an innovative player in obesity and metabolic disease treatments. The company develops next-generation injectable and oral hormone analog peptides designed for potency, scalability, and improved patient adherence.

In 2025, Metsera, Inc. (NASDAQ:MTSR)’s lead candidate, MET-233i, an ultra-long-acting amylin analog, showed promising Phase 1 results, with patients achieving up to 8% body weight reduction over five weeks. Its extended half-life supports once-monthly dosing, offering greater convenience and potential compliance benefits compared to existing therapies. MET-233i is being developed both as a standalone treatment and in combination with other obesity medicines in the business’s pipeline.

Metsera, Inc. (MTSR)’s MET-233i Shows 8% Weight Loss in Phase 1

Another key asset, the GLP-1 receptor agonist MET-097i, is progressing through multiple Phase 2b trials, with data readouts expected later in 2025 and Phase 3 trials planned to begin by year-end. The corporation is preparing to present these results at upcoming medical and investor conferences, signaling growing scientific and market interest.

While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.